Establishment and characterization of two novel patient‐derived lines from canine high‐grade glioma
Open Access
- 30 May 2023
- journal article
- research article
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 21 (3) , 492-502
Abstract
High‐grade glioma is an aggressive cancer that occurs naturally in pet dogs. Canine high‐grade glioma (cHGG) is treated with radiation, chemotherapy or surgery, but has no curative treatment. Within the past eight years, there have been advances in our imaging and histopathology standards as well as genetic charactereization of cHGG. However, there are only three cHGG cell lines publicly available, all of which were derived from astrocytoma and established using methods involving expansion of tumour cells in vitro on plastic dishes. In order to provide more clinically relevant cell lines for studying cHGG in vitro, the goal of this study was to establish cHGG patient‐derived lines, whereby cancer cells are expanded in vivo by injecting cells into immunocompromized laboratory mice. The cells are then harvested from mice and used for in vitro studies. This method is the standard in the human field and has been shown to minimize the acquisition of genetic alterations and gene expression changes from the original tumour. Through a multi‐institutional collaboration, we describe our methods for establishing two novel cHGG patient‐derived lines, Boo‐HA and Mo‐HO, from a high‐grade astrocytoma and a high‐grade oligodendroglioma, respectively. We compare our novel lines to G06‐A, J3T‐Bg, and SDT‐3G (traditional cHGG cell lines) in terms of proliferation and sensitivity to radiation. We also perform whole genome sequencing and identify an NF1 truncating mutation in Mo‐HO. We report the characterization and availability of these novel patient‐derived lines for use by the veterinary community.Keywords
Funding Information
- American Brain Tumor Association
- American Cancer Society
- Ohio State University
- Pelotonia
This publication has 23 references indexed in Scilit:
- Naturally Occurring Canine Glioma as a Model for Novel TherapeuticsCancer Investigation, 2018
- A Revised Diagnostic Classification of Canine Glioma: Towards Validation of the Canine Glioma Patient as a Naturally Occurring Preclinical Model for Human GliomaJournal of Neuropathology & Experimental Neurology, 2018
- Consensus recommendations on standardized magnetic resonance imaging protocols for multicenter canine brain tumor clinical trialsVeterinary Radiology & Ultrasound, 2018
- In vitroanti‐tubulin effects of mebendazole and fenbendazole on canine glioma cellsVeterinary and Comparative Oncology, 2017
- The Human Glioblastoma Cell Culture Resource: Validated Cell Models Representing All Molecular SubtypesEBioMedicine, 2015
- The growth of the canine glioblastoma cell line D‐GBM and the canine histiocytic sarcoma cell line DH82 is inhibited by the resveratrol oligomers hopeaphenol and r2‐viniferinVeterinary and Comparative Oncology, 2012
- TP53 Mutations in Canine Brain TumorsVeterinary Pathology, 2011
- Genomic Changes and Gene Expression Profiles Reveal That Established Glioma Cell Lines Are Poorly Representative of Primary Human GliomasMolecular Cancer Research, 2008
- Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell linesCancer Cell, 2006
- Tumorigenic, invasive, karyotypic, and immunocytochemical characteristics of clonal cell lines derived from a spontaneous canine anaplastic astrocytomaIn Vitro Cellular & Developmental Biology - Animal, 1993